VYNE THERAPEUTICS INC.

Analyst Reco. VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
2.640 ^USD	-4.00%		-6.71%	+13.30%

Nov. 18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
Nov. 07	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	Nov. 18	MT
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	23-05-12	MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	23-03-14	MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	22-08-10	MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target	21-12-06	MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating	21-08-13	MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating	21-05-07	MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating	21-03-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters